Zinzino has released its preliminary sales report for 2025, reporting strong top-line growth for 2025.
The Sweden-based company has reported exceptionally fast growth for a health and nutrition company, with its full-year 2025 revenue up 51% versus 2024.
Its Q4 revenue was up 46% year-on-year, with sales markets in December alone increasing by 35%, amounting to SEK 334.4m.
Including subsidiary operations, total group revenue for December amounted to SEK 337.3 million, representing a 33% increase compared with the same period last year.
External sales at Faun Pharma, part of the Zinzino Group, declined during the month to SEK 2.9 million, down from SEK 5.8 million a year earlier, although this had a limited impact on overall group performance.
The preliminary sales update points to sustained demand for Zinzino’s health and nutrition products and signals strong commercial momentum heading into 2026.
The company has not yet released full financial results for the year, with profitability, margins and cost performance expected to be detailed in its upcoming annual report.
Revenues were distributed as follows:
